“Patients with oesophageal cancer undergoing neoadjuvant chemoradiotherapy and surgery
are at substantial risk of thromboembolic and bleeding events throughout all stages of treatment. Survival is worse in patients with thromboembolic events during follow-up.”

“In this study, the risk of thromboembolic and bleeding events was considerable in patients with oesophageal cancer receiving treatment with curative intent. By 24 months of follow-up, VTE had been diagnosed in 9⋅8 per cent of patients, arterial thromboembolism in 3⋅9 per cent, major bleeding in 4⋅1 per cent and clinically relevant non-major bleeding in 5⋅9 per cent. During follow-up, 21⋅1 per cent of patients were affected by any of these complications. This risk was present during all treatment phases, includ- ing the time from cancer diagnosis to first chemoradiation and the neoadjuvant treatment stage, but was highest in the 30 days after surgery.”

Mulder FI, et al Thromboembolic and bleeding complications in patients with oesophageal cancer. Br J Surg. 2020 Sep;107(10):1324-1333. Free Full Text